(PSYCHIATRIC TIMES) - MedPage Today Action Points
SAN DIEGO, May 22 -- The key to the efficacy of atypical or second-generation antipsychotic agents in treatment of schizophrenia is their affinity for binding to and occupying the dopamine D2 receptor.
So said Gordon Frankle, M.D., of the University of Pittsburgh. Dr. Frankle discussed the neurobiology of schizophrenia at a satellite symposium presented in conjunction with the American Psychiatric Association meeting here.
All currently approved antipsychotic agents decrease dopamine activity at the synapse, and all have activity on the dopamine D2 receptor, he said.
For full article, please visit: